NatureWise Biotech & Medicals Corporation engages in the development of therapeutic drugs in Taiwan.
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$22.15|
|52 Week High||NT$20.00|
|52 Week Low||NT$30.33|
|1 Month Change||3.89%|
|3 Month Change||-1.97%|
|1 Year Change||-21.34%|
|3 Year Change||17.04%|
|5 Year Change||12.61%|
|Change since IPO||28.51%|
Recent News & Updates
Lacklustre Performance Is Driving NatureWise Biotech & Medicals Corporation's (GTSM:4732) Low P/E
With a price-to-earnings (or "P/E") ratio of 16.8x NatureWise Biotech & Medicals Corporation ( GTSM:4732 ) may be...
A Look At The Intrinsic Value Of NatureWise Biotech & Medicals Corporation (GTSM:4732)
How far off is NatureWise Biotech & Medicals Corporation ( GTSM:4732 ) from its intrinsic value? Using the most recent...
|4732||TW Personal Products||TW Market|
Return vs Industry: 4732 underperformed the TW Personal Products industry which returned -17% over the past year.
Return vs Market: 4732 underperformed the TW Market which returned 33.6% over the past year.
Stable Share Price: 4732 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 4732's weekly volatility (5%) has been stable over the past year.
About the Company
NatureWise Biotech & Medicals Corporation engages in the development of therapeutic drugs in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; PPL products comprise Taiwanese Green Propolis; and NBM-BMX an oral Softgel capsule to treat cancer. The company was founded in 2000 and is based in Taipei City, Taiwan.
NatureWise Biotech & Medicals Fundamentals Summary
|4732 fundamental statistics|
Is 4732 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4732 income statement (TTM)|
|Cost of Revenue||NT$79.46m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0054|
|Net Profit Margin||-0.14%|
How did 4732 perform over the long term?See historical performance and comparison
0.4%Current Dividend Yield
Is NatureWise Biotech & Medicals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 4732 (NT$22.15) is trading above our estimate of fair value (NT$12.11)
Significantly Below Fair Value: 4732 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 4732 is unprofitable, so we can't compare its PE Ratio to the TW Personal Products industry average.
PE vs Market: 4732 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4732's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4732 is good value based on its PB Ratio (1.9x) compared to the TW Personal Products industry average (2x).
How is NatureWise Biotech & Medicals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NatureWise Biotech & Medicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has NatureWise Biotech & Medicals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4732 is currently unprofitable.
Growing Profit Margin: 4732 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4732 is unprofitable, but has reduced losses over the past 5 years at a rate of 64% per year.
Accelerating Growth: Unable to compare 4732's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4732 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (17.9%).
Return on Equity
High ROE: 4732 has a negative Return on Equity (-0.045%), as it is currently unprofitable.
How is NatureWise Biotech & Medicals's financial position?
Financial Position Analysis
Short Term Liabilities: 4732's short term assets (NT$558.3M) exceed its short term liabilities (NT$44.2M).
Long Term Liabilities: 4732's short term assets (NT$558.3M) exceed its long term liabilities (NT$10.9M).
Debt to Equity History and Analysis
Debt Level: 4732 is debt free.
Reducing Debt: 4732 has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 4732 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 4732 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 44.2% per year.
What is NatureWise Biotech & Medicals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 4732's dividend (0.43%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.93%).
High Dividend: 4732's dividend (0.43%) is low compared to the top 25% of dividend payers in the TW market (5.25%).
Stability and Growth of Payments
Stable Dividend: 4732 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.
Growing Dividend: 4732 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 4732 is not paying a notable dividend for the TW market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4732's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Chung-Yang Huang, Ph.D. MBA serves as Chief Executive Officer of Naturewise Biotech & Medicals Corp.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
NatureWise Biotech & Medicals Corporation's employee growth, exchange listings and data sources
- Name: NatureWise Biotech & Medicals Corporation
- Ticker: 4732
- Exchange: TPEX
- Founded: 2000
- Industry: Personal Products
- Sector: Household
- Market Cap: NT$1.092b
- Shares outstanding: 49.29m
- Website: https://www.naturewise.com.tw
Number of Employees
- NatureWise Biotech & Medicals Corporation
- No. 36, Bade Road
- 6th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 08:32|
|End of Day Share Price||2021/09/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.